Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
IPO Year: 2000
Exchange: NASDAQ
Website: cgen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/5/2022 | $2.00 | Buy → Hold | Jefferies |
| 2/25/2022 | $17.00 → $14.00 | Outperform | Oppenheimer |
| 2/25/2022 | $16.00 → $9.00 | Outperform | SVB Leerink |
HOLON, Israel, Oct. 29, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its third quarter 2024 financial results on Tuesday, November 12, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the financial results and provide a corporate update at 8:30 am ET. As part of the update, management will discuss Compugen's data that will have been presented at the Annual Meeting of the Society for Immunotherapy of Cancer, being held on November 8-10, 2024. To access the live conference call by telepho
HOLON, Israel, Oct. 7, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that new clinical data supporting the anti-tumor activity and safety of the triple combination COM701, COM902 and pembrolizumb in heavily pre-treated patients with platinum resistant ovarian cancer will be presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between November 8-10, 2024, in Houston, Texas. Poster presentation details: Abstract Title: Triple blockade of DNAM-1axis with COM701 (anti-PVRIG) + COM902 (anti-TIGIT) + pembrolizumab shows pre
HOLON, Israel, Sept. 9, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Dr. Roy Granit, Head of Computational Discovery at Compugen will present a poster on applying AI to gain insights into the novel immune checkpoint PVRIG through single-cell and spatial transcriptomics at the Single Cell Genomics 2024 conference taking place between September 16-18, 2024, Corinthia, Greece. Additional biological insights characterizing the uniqueness of the novel immune checkpoint PVRIG discovered by Compugen, were generated using Compugen's AI/ML-powered computational disco
HOLON, Israel, Aug. 29, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available on demand on the Investor Relations section of Compugen's website at www.cgen.com from Monday, September 9, 2024, 7:00 AM ET for 30 days. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways
FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study in Q4 2024Partner, AstraZeneca, advanced development of rilvegostomig, and provided a non-risk adjusted peak year revenue target of over $5 billion, reflecting the potential of the asset. Compugen is eligible for future milestones and mid-single-digit tiered royalty payments, presenting a significant potential revenue source for the CompanySolid balance sheet with cash runway expected to fund operations into 2027HOLON, Israel, Aug. 6, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a
FDA clearance triggers a $30 million milestone payment from GileadCompany on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harness cytokine biology for cancer therapeutics as monotherapy and in combination in advanced solid tumors in Q4 2024HOLON, Israel, July 29, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to initiate a Phase 1 trial for COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibo
HOLON, Israel, July 23, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its second quarter 2024 financial results on Tuesday, August 6, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link. Following the
HOLON, Israel, June 17, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Pierre Ferré, Ph.D, SVP, Preclinical Development and Corporate Operations, Compugen will present a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies at the Antibody Industrial Symposium taking place June 20-21, 2024, Montpellier, France. Event: 12th Antibody Industrial Symposium, Montpellier, FranceDate: Friday, June 21, 2024Presenter: Pierre Ferré, Ph.D., SVP, Preclinical Development and Corporate Operations, CompugenPresentation title: Case study on cli
Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancerBroadening the assessment of rilvegostomig reinforces Compugen's partnering strategy to expand opportunities for its pipelineCompugen to receive $5 million milestone payment from AstraZenecaHOLON, Israel, May 30, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it is entitled to receive a milestone payment from AstraZeneca (NASDAQ:AZN) triggered by the dosing of the first patient in a P
Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study in Q4 2024Data from COM701 + COM902 + pembrolizumab study in microsatellite stable colorectal cancer with liver metastases planned to be presented at ASCO 2024 annual meetingOn track to submit IND for COM503 in the second half of 2024 with preparation for Phase 1 study well advancedPartner, AstraZeneca, progressed rilvegostomig into second Phase 3 trial in nonsquamous NSCLC; Compugen eligible for development milestone payments for this second indicationSolid balance sheet with extended cash runway expected to fund operations into 2027HOLON, Israel, May 20, 2024 /PRNe
Jefferies downgraded Compugen from Buy to Hold and set a new price target of $2.00
Oppenheimer reiterated coverage of Compugen with a rating of Outperform and set a new price target of $14.00 from $17.00 previously
SVB Leerink reiterated coverage of Compugen with a rating of Outperform and set a new price target of $9.00 from $16.00 previously
SVB Leerink reiterated coverage of Compugen with a rating of Outperform and set a new price target of $16.00 from $19.00 previously
6-K - COMPUGEN LTD (0001119774) (Filer)
6-K - COMPUGEN LTD (0001119774) (Filer)
6-K - COMPUGEN LTD (0001119774) (Filer)
6-K - COMPUGEN LTD (0001119774) (Filer)
6-K - COMPUGEN LTD (0001119774) (Filer)
6-K - COMPUGEN LTD (0001119774) (Filer)
6-K - COMPUGEN LTD (0001119774) (Filer)
20-F - COMPUGEN LTD (0001119774) (Filer)
6-K - COMPUGEN LTD (0001119774) (Filer)
6-K - COMPUGEN LTD (0001119774) (Filer)
HOLON, Israel, May 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024, taking over from Alberto Sessa who will depart Compugen on the same day. David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer. "I am excited to welcome David to Compugen and believe his experience and insights will make him a pivotal additio
HOLON, Israel, Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen. "I am delighted that Michelle will join the management team as Chief Medical Officer at a very exciting time for Compugen," said Anat Coh
HOLON, Israel, Sept. 12, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Alberto Sessa has been appointed Chief Financial Officer (CFO) and member of the management team. Alberto will join Compugen on November 1, 2022. "I am delighted to have a financial executive of Alberto's expertise and experience join Compugen and strengthen our management team," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen. "His extensive experience and track record in leading financing, investor relations, M&A, and business development transactions and providing stra
HOLON, Israel, Feb. 24, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol Myers Squibb, to its Board of Directors effective March 1, 2022. In addition, the Company announced that Dr. Jean-Pierre Bizzari will retire from its Board of Directors. "I am delighted to welcome Math to Compugen's Board," said Paul Sekhri, Chairman of the Board. "His considerable experience in immuno-oncology drug development including involvement in five b
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)
SC 13G - COMPUGEN LTD (0001119774) (Subject)
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)
SC 13G/A - COMPUGEN LTD (0001119774) (Subject)
HOLON, Israel, Oct. 29, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its third quarter 2024 financial results on Tuesday, November 12, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the financial results and provide a corporate update at 8:30 am ET. As part of the update, management will discuss Compugen's data that will have been presented at the Annual Meeting of the Society for Immunotherapy of Cancer, being held on November 8-10, 2024. To access the live conference call by telepho
FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study in Q4 2024Partner, AstraZeneca, advanced development of rilvegostomig, and provided a non-risk adjusted peak year revenue target of over $5 billion, reflecting the potential of the asset. Compugen is eligible for future milestones and mid-single-digit tiered royalty payments, presenting a significant potential revenue source for the CompanySolid balance sheet with cash runway expected to fund operations into 2027HOLON, Israel, Aug. 6, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a
HOLON, Israel, July 23, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its second quarter 2024 financial results on Tuesday, August 6, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link. Following the
Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study in Q4 2024Data from COM701 + COM902 + pembrolizumab study in microsatellite stable colorectal cancer with liver metastases planned to be presented at ASCO 2024 annual meetingOn track to submit IND for COM503 in the second half of 2024 with preparation for Phase 1 study well advancedPartner, AstraZeneca, progressed rilvegostomig into second Phase 3 trial in nonsquamous NSCLC; Compugen eligible for development milestone payments for this second indicationSolid balance sheet with extended cash runway expected to fund operations into 2027HOLON, Israel, May 20, 2024 /PRNe
HOLON, ISRAEL, May 6, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2024 financial results on Monday, May 20, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S.,or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link. Following the live w
Partnership with Gilead on preclinical immuno-oncology program further validates Compugen's computational discovery, research, and development capabilitiesCatalyst rich 2024 expected with multiple data readouts and updates planned from Compugen's diversified portfolioSolid balance sheet with extended cash runway expected to fund operations into 2027HOLON, Israel, March 5, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today reported financial results for the fourth quarter and full year 2023 and provided a corporate update. "Our accomplishments in 2023 position us well for an exciti
HOLON, Israel, Feb. 20. 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link.
Conference call today, December 19, 2023, 8:30 AM ET to discuss the license agreementHOLON, Israel, Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will host a conference call at 8:30 AM ET today, to discuss the exclusive license agreement with Gilead announced today, for the development and commercialization of its anti-IL-18 binding protein program including COM503, a pre-clinical potential first-in-class high affinity antibody targeting IL-18 binding protein with potential to treat multiple tumor types. Conference Call Details To access the live c
Advancing enrollment in two proof-of-concept studies evaluating triple blockade of DNAM-1 axis in patients with microsatellite stable colorectal cancer and platinum resistant ovarian cancer; initial findings expected by year end Data from multiple studies planned to be presented by the end of the year: - New data from metastatic breast cancer study evaluating COM701+ nivolumab - New translational data and initial biomarker data from platinum resistant ovarian cancer studies evaluating COM701 + nivolumab ± BMS anti-TIGIT - Longer-term patient follow up from platinum resistant ovarian cancer study evaluating COM701 + nivolumab + BMS anti-TIGIT - New data from COM503 lead p
HOLON, Israel, July 24, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its second quarter financial results on Monday, August 7, 2023, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link. Following the live w
Truist Securities analyst Asthika Goonewardene maintains Compugen (NASDAQ:CGEN) with a Buy and lowers the price target from $5 to $4.
David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer.
Truist Securities analyst Asthika Goonewardene maintains Compugen (NASDAQ:CGEN) with a Buy and raises the price target from $4 to $5.
Compugen (NASDAQ:CGEN) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.23 by 52.17 percent. This is a 375 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $33.46 million which beat the analyst consensus estimate of $20.00 million by 67.30 percent. This is a 346.12 percent increase over sales of $7.50 million the same period last year.
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. • Target (NYSE:TGT) is estimated to report quarterly earnings at $2.22 per share on revenue of $29.33 billion. • 2seventy bio (NASDAQ:TSVT) is expected to report quarterly loss at $0.99 per share on revenue of $14.71 million. • CLPS (NASDAQ:CLPS) is expected to report earnings for its first quarter. • Seres Therapeutics (NASDAQ:MCRB) is projected to report quarterly loss at $0.50 per share on revenue of $350 thousand. • Vivid Seats (NASDAQ:SEAT) is expected to report quarterly earnings at $0.06 per share on revenue of $183.67 million. • Nuwellis (N